Literature DB >> 18316951

Gastrointestinal surgery as treatment for type 2 diabetes.

Tracy-Ann Moo1, Francesco Rubino.   

Abstract

PURPOSE OF REVIEW: As the incidence of type 2 diabetes continues to rise worldwide at epidemic proportions, endeavors to find more effective therapies increase. Gastrointestinal bypass surgery is now gaining awareness as a potential effective and long-term treatment. RECENT
FINDINGS: There is now a substantial body of evidence supporting the efficacy of gastrointestinal surgery in controlling type 2 diabetes. This is well documented in several studies of obese diabetic patients undergoing gastrointestinal bypass procedures. Additionally, smaller studies and case reports also demonstrate the efficacy of gastrointestinal bypass surgery in nonobese diabetic patients. The pathophysiologic basis of the improvement in diabetes after gastrointestinal bypass surgery is still unclear; however, the dominant hypotheses involve changes in hormone signaling from the small bowel.
SUMMARY: The implications of 'diabetes surgery' are vast, and could dramatically change the face of diabetes as we know it today. In clinical practice surgery could represent an alternative for the treatment of diabetes. On a broader perspective, surgery may facilitate research aimed at understanding the etiology of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316951     DOI: 10.1097/MED.0b013e3282f88a0a

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  21 in total

1.  Roux-en-Y gastric bypass promotes expression of PDX-1 and regeneration of beta-cells in Goto-Kakizaki rats.

Authors:  Zhen Li; Hong-Ya Zhang; Lu-Xian Lv; Dong-Fei Li; Jing-Xing Dai; Ou Sha; Wen-Qiang Li; Yu Bai; Lin Yuan
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery.

Authors:  Andrew C Shin; Huiyuan Zheng; R Leigh Townsend; David L Sigalet; Hans-Rudolf Berthoud
Journal:  Endocrinology       Date:  2010-02-23       Impact factor: 4.736

3.  Bariatric surgery--not to be taken lightly.

Authors:  Shahrad Taheri; Harish Kumar; Sue Bridgwater; Anthony Barnett
Journal:  J R Soc Med       Date:  2009-01       Impact factor: 5.344

4.  Changes in glucose transporters, gluconeogenesis, and circadian clock after duodenal-jejunal bypass surgery.

Authors:  Mikyung Kim; Young Gil Son; Yu Na Kang; Tae Kyung Ha; Eunyoung Ha
Journal:  Obes Surg       Date:  2015-04       Impact factor: 4.129

Review 5.  Obesity surgery and gut-brain communication.

Authors:  Hans-Rudolf Berthoud; Andrew C Shin; Huiyuan Zheng
Journal:  Physiol Behav       Date:  2011-02-24

Review 6.  Bariatric surgery: risks and rewards.

Authors:  Walter J Pories
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

7.  Clinical efficacy of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass in obese type 2 diabetic patients: a retrospective comparison.

Authors:  P P Cutolo; G Nosso; G Vitolo; V Brancato; B Capaldo; L Angrisani
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

8.  Improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation.

Authors:  Arthur Bohdjalian; Gerhard Prager; Christoph Rosak; Rudolf Weiner; Ralf Jung; Markus Schramm; Ricardo Aviv; Karin Schindler; Walid Haddad; Norbert Rosenthal; Bernhard Ludvik
Journal:  Obes Surg       Date:  2009-07-03       Impact factor: 4.129

Review 9.  Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus.

Authors:  Francesco Rubino; Sarah L R'bibo; Federica del Genio; Madhu Mazumdar; Timothy E McGraw
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

10.  Successful multi-intervention treatment of severe obesity: a 7-year prospective study with 96% follow-up.

Authors:  Rudolf Steffen; Natascha Potoczna; Norman Bieri; Fritz F Horber
Journal:  Obes Surg       Date:  2008-09-16       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.